Han B.,Jiangsu University |
Xu S.-R.,Affiliated Hospital of Jiangsu Province |
Zhang J.,Affiliated Hospital of Jiangsu Province |
Zhou Q.,Affiliated Hospital of Jiangsu Province |
Li W.,Jiangsu University
Chinese Journal of Tissue Engineering Research | Year: 2013
BACKGROUND: Immunity of fetal liver stem cell transplantation is rarely reported, syngeneic and allogeneic fetal liver stem cell transplantation in the treatment of hepatic cirrhosis is still unclear. OBJECTIVE: To observe the therapeutic effects of syngeneic and allogeneic fetal liver stem cell transplantation on hepatic cirrhosis as well as immune rejections during the therapeutic process. METHODS: The fetal liver stem/progenitor cells from BALB/c and C57BL/6 mice were isolated and purified by the type IV collagen enzyme digestion method. A total of 104 healthy BALB/c mice were randomly assigned to four groups. Normal control group: no treatment; Hepatic cirrhosis group, syngeneic transplantation group and allogeneic transplantation group: 16 weeks after hepatic cirrhosis models of mice were developed by intraperitoneal injection with carbon tetrachloride, physiological saline, syngeneic fetal liver stem cells and allogeneic fetal liver stem cells were injected via the caudal vein. Finally, the survival statuses, liver function, hepatic fibrosis index, the number and ratio of immune cells (CD4+T, CD8+T, NK, NKT) and histopathologic examinations were compared in each group after transplantation 4 weeks. RESULTS AND CONCLUSION: The survival rates in the two transplantation groups were both 100%, which was significantly higher than that in the hepatic cirrhosis group (67%, P < 0.05). The liver function and liver fibrosis index in each group did not show statistical differences (P > 0.05). Immunological tests showed no difference between groups (P > 0.05). Pathohistology examination of hepatic tissue repair: Allogeneic transplantation group > syngeneic transplantation group > hepatic cirrhosis group. Hence, fetal liver stem cell transplantation via the caudal vein could elevate the survival rate of hepatic cirrhosis mice, alleviate the degree of hepatocyte necrosis. There is no immunologic rejection during syngeneic and allogeneic fetal liver stem cell transplantation that could help to treat hepatic cirrhosis in mice.